Blurbs

Inhibrx (INBX) Receives a Buy from JMP Securities

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Inhibrx (INBXResearch Report) today and set a price target of $40.00. The company’s shares closed yesterday at $29.76.

According to TipRanks, Benjamin is an analyst with an average return of -12.5% and a 29.67% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Incyte, Blueprint Medicines, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Inhibrx is a Strong Buy with an average price target of $44.33.

See Insiders’ Hot Stocks on TipRanks >>

INBX market cap is currently $788.2M and has a P/E ratio of -7.06.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates.

Read More on INBX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed